Antibody–oligonucleotide conjugates (AOCs) are an emerging class of targeted therapeutics that combine the precision of antibodies with the functional versatility of oligonucleotides. This case study highlights a successful AOC development program that overcame the inherent complexity of these large, charged, and structure sensitive moleculesdelivering well defined conjugates with controlled oligonucleotide to antibody ratio and high purity.

Key Highlights

• Precise Conjugation Control: Achieved defined OAR with minimal species heterogeneity, enabling reliable product quality.
• Dual Route Strategy: Demonstrated flexibility across two distinct conjugation platforms, supporting informed route selection.
• Efficient Purification & High Recovery: Delivered pure AOC materials with excellent yields while preserving antibody integrity.
• Analytical Confidence: Provided robust characterization to confirm identity, purity, and impurity profiles, reducing uncertainty in complex conjugate analysis.

Download the full case study to see how controlled AOC synthesis can be delivered with confidence.